Introduction
============

A complex disorder resulting from the combined effects of multiple environmental and genetic factors, prostate cancer is the second-leading cause of cancer death in men.[@b1-cmar-10-5247] The underlying etiology of prostate cancer is still poorly understood. Genome-wide association studies on the genetic etiology of cancer have discovered some heritability of different cancer types.[@b2-cmar-10-5247] Single-nucleotide substitution, a kind of alteration in genetic sequence, can lead to cancer formation through biologically regulating a handful of molecular activities.[@b3-cmar-10-5247]

A family of zinc endopeptidases, MMPs can cleave nearly all components of the extracellular matrix, as well as many other soluble and cell-associated proteins.[@b4-cmar-10-5247] MMPs play important roles in cancer development, invasion, and metastasis.[@b5-cmar-10-5247] At the genetic level, a number of studies have been carried out to assess associations between polymorphisms of MMPs and prostate cancer risk,[@b6-cmar-10-5247]--[@b14-cmar-10-5247] but conclusions have been conflicting and inconclusive. For example, Srivastava et al found the MMP2 rs243865 polymorphism contributed to prostate cancer susceptibility,[@b10-cmar-10-5247] while Adabi et al found no association between MMP2 rs243865 polymorphism and prostate cancer risk.[@b11-cmar-10-5247] Individual studies with small samples may result in incorrect conclusions. Therefore, a comprehensive meta-analysis and systematic review were necessary to assess relationships between MMP polymorphisms and prostate cancer risk precisely.

Methods
=======

Search strategy
---------------

The entire process of this meta-analysis and systematic review followed the guidelines of the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement ([Table S1](#SD1-cmar-10-5247){ref-type="supplementary-material"}).[@b15-cmar-10-5247] The databases PubMed, Embase, and Web of Knowledge were searched with the following search terms: (MMP OR MMPs OR matrix metalloproteinase OR matrix metalloproteinases) AND (polymorphism OR polymorphisms OR single nucleotide polymorphism OR single nucleotide polymorphisms) AND (prostate cancer OR prostate carcinoma). The last search was on August 3, 2018. Additional published data were identified by reviewing references listed in each article. The literature search was performed by two investigators independently. Disagreement was resolved by discussion.

Inclusion and exclusion criteria
--------------------------------

Inclusion criteria for this study were a focus on associations between MMP polymorphisms and prostate cancer risk, case--control design, available frequency of each genotype provided in both case and control groups to calculate OR and corresponding 95% CI, and written in English. Exclusion criteria were reviews, editorials, comments, and animal studies and overlap with another included article.

Data extraction
---------------

Two investigators independently extracted author names, year of publication, country of origin, case-group sample type, source of control group, genotyping method, type of MMPs, names of polymorphisms, number of cases and controls, Hardy--Weinberg equilibrium (HWE) values, and frequency of genotypes. Consensus on extracted items was reached by discussion between the two investigators.

Quality assessment
------------------

The quality of each included study was assessed according to the quality-assessment criteria in [Table S2](#SD2-cmar-10-5247){ref-type="supplementary-material"}.[@b16-cmar-10-5247] Quality scores of studies ranged from 0 to 15, and studies with scores ≥9 were regarded as being of high quality.

Statistical analysis
--------------------

Meta-analysis was performed unless at least two studies concerning the same MMP polymorphism were included; otherwise, a systematic review was carried out. Pooled ORs and 95% CIs were calculated under five comparison models: homozygote, heterozygote, dominant, recessive, and additive. Pooled ORs assessed by *Z*-test were considered significant at *P*\<0.05. HWE in the control group was checked by *χ*^2^ test, and disequilibrium was deemed present at *P*\<0.05. Heterogeneity assumption was checked by a *χ*^2^-based *Q*-statistic test and quantified by *I*^2^ values. If *I*^2^\<50% or *Q*-test *P*\>0.10, the -effect model was used. Otherwise, a random-effect model was used. Subgroup analysis by case-group sample type was also performed. Funnel plots and Egger's test were undertaken to examine publication bias. Publication bias was considered at *P*\<0.05 for Egger's test. Statistical analyses for this paper were completed with Stata (College Station, TX, USA) version 12.0.

Results
=======

Literature search and study characteristics
-------------------------------------------

[Figure 1](#f1-cmar-10-5247){ref-type="fig"} shows the selection process. A total of 26 articles were identified through the search strategy.[@b6-cmar-10-5247]--[@b14-cmar-10-5247],[@b17-cmar-10-5247]--[@b33-cmar-10-5247] Nine articles were removed based on the title or abstract,[@b17-cmar-10-5247]--[@b25-cmar-10-5247] and the 17 remaining articles were screened for full text. Among these 17 articles,[@b6-cmar-10-5247]--[@b14-cmar-10-5247],[@b26-cmar-10-5247]--[@b33-cmar-10-5247] only eleven met inclusion criteria, because four did not have a control group,[@b26-cmar-10-5247]--[@b29-cmar-10-5247] one overlapped with another,[@b30-cmar-10-5247] and one did not provide available frequency of each genotype in either the case group or control group.[@b31-cmar-10-5247] Ultimately, eleven articles encompassing 22 studies[@b6-cmar-10-5247]--[@b14-cmar-10-5247],[@b32-cmar-10-5247],[@b33-cmar-10-5247] and involving 12 polymorphisms were included in this paper. Their characteristics are listed in [Table 1](#t1-cmar-10-5247){ref-type="table"}. Definitions of comparison models for the studies are listed in [Table S3](#SD3-cmar-10-5247){ref-type="supplementary-material"}, and frequencies of genotypes from the meta-analysis and systematic review in [Tables S4](#SD4-cmar-10-5247){ref-type="supplementary-material"} and [S5](#SD5-cmar-10-5247){ref-type="supplementary-material"}, respectively.

Among the included studies, 13 studies with three polymorphisms (five for MMP1 rs1799750 involving 853 prostate cancer cases and 1,027 controls, six for MMP2 rs243865 involving 699 prostate cancer cases and 734 controls, and two for MMP7 rs11568818 involving 297 prostate cancer cases and 297 controls) were quantitatively synthesized for meta-analysis.[@b6-cmar-10-5247],[@b8-cmar-10-5247]--[@b10-cmar-10-5247],[@b12-cmar-10-5247]--[@b14-cmar-10-5247],[@b32-cmar-10-5247],[@b33-cmar-10-5247] The remaining nine studies with nine polymorphisms (MMP2 rs2285053, MMP2 rs1477017, MMP2 rs17301608, MMP2 rs11639960, MMP3 1171-5A/6A, MMP3 1161A/G, MMP3 5356A/G, MMP9 rs17576, and MMP13 rs2252070) involving 2,054 prostate cancer cases and 2,138 controls could not be quantitatively synthesized, and so the systematic review was performed.[@b7-cmar-10-5247],[@b8-cmar-10-5247],[@b10-cmar-10-5247],[@b11-cmar-10-5247],[@b33-cmar-10-5247]

Meta-analysis
-------------

The results of meta-analysis for MMP1 rs1799750 ([Table 2](#t2-cmar-10-5247){ref-type="table"}, [Figure 2](#f2-cmar-10-5247){ref-type="fig"}) showed that no significant associations were found in overall people (homozygote model, OR 1.16, 95% CI 0.91--1.47, *P*=0.237; heterozygote model, OR 1.12, 95% CI 0.94--1.33, *P*=0.223; dominant model, OR 1.09, 95% CI 0.94--1.27, *P*=0.251; recessive model, OR 1.09, 95% CI 0.87--1.37, *P*=0.471; additive model, OR 1.09, 95% CI 0.97--1.23, *P*=0.163). When the studies were stratified according to blood samples of case groups ([Table 2](#t2-cmar-10-5247){ref-type="table"}, [Figure 2](#f2-cmar-10-5247){ref-type="fig"}), no associations existed in any comparison model. Subgroups of tissue samples could not be assessed, because there was only one study included.

For the MMP2 rs243865 polymorphism ([Table 3](#t3-cmar-10-5247){ref-type="table"}, [Figure 3](#f3-cmar-10-5247){ref-type="fig"}), meta-analysis showed no significant associations were found in people overall (homozygote model, OR 1.00, 95% CI 0.84--1.20, *P*=0.97; heterozygote model, OR 1.08, 95% CI 0.84--1.40, *P*=0.54; dominant model, OR 1.01, 95% CI 0.87--1.18, *P*=0.875; recessive model, OR 0.90, 95% CI 0.76--1.06, *P*=0.206; additive model, OR 0.96, 95% CI 0.86--1.08, *P*=0.521). Subgroup analysis by case-group sample type confirmed that no associations existed in any comparison model matter for blood or tissue samples ([Table 3](#t3-cmar-10-5247){ref-type="table"}, [Figure 3](#f3-cmar-10-5247){ref-type="fig"}).

For MMP7 rs11568818 ([Table 4](#t4-cmar-10-5247){ref-type="table"}, [Figure 4](#f4-cmar-10-5247){ref-type="fig"}), no significant associations were found in people overall (homozygote model, OR 0.95, 95% CI 0.67--1.37, *P*=0.796; heterozygote model, OR 0.98, 95% CI 0.72--1.33, *P*=0.908; dominant model, OR 0.99, 95% CI 0.77--1.26, *P*=0.917; recessive model, OR 0.91, 95% CI 0.66--1.27, *P*=0.592; additive model, OR 0.97, 95% CI 0.80--1.17, *P*=0.72). Subgroup analysis by case-group sample type was not performed.

Heterogeneity analysis
----------------------

For MMP1 rs1799750, MMP2 rs243865, and MMP7 rs11568818 polymorphisms, there was no obvious heterogeneity in any comparison model for people overall or for subgroup analyses ([Tables 2](#t2-cmar-10-5247){ref-type="table"}[](#t3-cmar-10-5247){ref-type="table"}--[4](#t4-cmar-10-5247){ref-type="table"}).

Publication-bias analysis
-------------------------

For MMP1 rs1799750, funnel plots ([Figure 5](#f5-cmar-10-5247){ref-type="fig"}) and Egger's tests suggested no evidence of publication bias (homozygote model, *P*=0.27; heterozygote model, *P*=0.187; dominant model, *P*=0.199; recessive model, *P*=0.351; additive model, *P*=0.226).

For MMP2 rs243865, funnel plots ([Figure 6](#f6-cmar-10-5247){ref-type="fig"}) and Egger's tests (homozygote model, *P*=0.87; heterozygote model, *P*=0.864; dominant model, *P*=0.879; recessive model, *P*=0.826; additive model, *P*=0.927) suggested no evidence of publication bias in the meta-analysis either.

For MMP7 rs11568818, publication-bias analysis was not conducted for the two studies involved.

Systematic review
-----------------

In the systematic review ([Table 5](#t5-cmar-10-5247){ref-type="table"}), two polymorphisms (MMP3 1171-5A/6A and MMP9 rs17576) were reported to be associated with prostate cancer risk, while another seven polymorphisms (MMP2 rs2285053, MMP2 rs1477017, MMP2 rs17301608, MMP2 rs11639960, MMP3 1161A/G, MMP3 5356A/G, and MMP13 rs2252070) were not associated with prostate cancer risk.

Discussion
==========

Srivastava et al showed that MMP2 rs243865 polymorphism contributed to prostate cancer susceptibility,[@b10-cmar-10-5247] while Adabi et al showed no association between MMP2 rs243865 polymorphism and prostate cancer risk.[@b13-cmar-10-5247] Therefore, a comprehensive meta-analysis and systematic review were necessary. As a powerful tool for summarizing different studies, meta-analysis and systematic review refer to the use of statistical techniques to integrate results of included studies.[@b15-cmar-10-5247]

This meta-analysis of five studies for MMP1 rs1799750, six studies for MMP2 rs243865 and two studies for MMP7 rs11568818 demonstrated that MMP1 rs1799750, MMP2 rs243865 polymorphisms and MMP7 rs11568818 were not associated with prostate cancer. Subgroup analysis by case-group sample type confirmed that no associations existed in any comparison model. We attributed the negative conclusions of our meta-analysis to two factors: firstly, only articles in English were included, and thus other related articles failed to be included; and secondly, some lower-quality studies were included, resulting in unpersuasive conclusions.

Although this systematic review of nine studies involving nine polymorphisms revealed that MMP3 1171 5A/6A and MMP9 rs17576 were associated with prostate cancer risk, its conclusion needs more research to support it, because each polymorphism had only one study. MMP9 can produce prostate cancer indirectly via triggering TGFβ activation, because an increase in TGFβ signaling will lead to cancer development and progession.[@b34-cmar-10-5247],[@b35-cmar-10-5247]

We noticed two previous meta-analyses had investigated the relationships of MMP1 rs1799750 or MMP2 rs243865 and prostate cancer risk.[@b17-cmar-10-5247],[@b18-cmar-10-5247] We read these carefully with great interest. Neither included other MMP polymorphisms, except for MMP1 rs1799750 and MMP2 rs243865.[@b17-cmar-10-5247],[@b18-cmar-10-5247] For MMP2 rs243865, our meta-analysis did not enroll the study by Jacobs et al, because it did not provide available frequency of genotypes.[@b7-cmar-10-5247] Conversely, both the previous meta-analyses included this study and thus concluded significant association.[@b17-cmar-10-5247],[@b18-cmar-10-5247] For MMP1 rs1799750, our paper enrolled two additional studies[@b32-cmar-10-5247],[@b33-cmar-10-5247] compared with one previous meta-analysis,[@b17-cmar-10-5247] and obtained a similar result. The major strengths of our paper lie in focusing on the relationship between MMP polymorphisms and prostate cancer risk comprehensively and systematically.

Some limitations still existed in our paper. First, several included studies contained small samples, which could lead to unpersuasive conclusions. Second, departure from HWE was detected in some studies. Third, there was a lack of a unified criterion for including studies.

Conclusion
==========

In summary, our paper shows that MMP polymorphisms are not associated with prostate cancer risk, except for MMP3 1171-5A/6A and MMP9 rs17576. However, it is necessary to conduct more large-scale and high-quality studies in future.

Supplementary materials
=======================

###### 

PRISMA checklist

  Section/topic                        \#   Checklist item                                                                                                                                                                                                                                                                                            Reported on page \#
  ------------------------------------ ---- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  **Title**                                                                                                                                                                                                                                                                                                                                           
  Title                                1    Identify the report as a systematic review, meta-analysis, or both.                                                                                                                                                                                                                                       1
  **Abstract**                                                                                                                                                                                                                                                                                                                                        
  Structured summary                   2    Provide a structured summary including, as applicable: background, objectives, data sources, study-eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings, systematic review registration number.   2--3
  **Introduction**                                                                                                                                                                                                                                                                                                                                    
  Rationale                            3    Describe the rationale for the review in the context of what is already known.                                                                                                                                                                                                                            3
  Objectives                           4    Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).                                                                                                                                                3--4
  **Methods**                                                                                                                                                                                                                                                                                                                                         
  Protocol and registration            5    Indicate if a review protocol exists, if and where it can be accessed (eg, web address), and if available provide registration information, including registration number.                                                                                                                                
  Eligibility criteria                 6    Specify study characteristics (eg, PICOS, length of follow-up) and report characteristics (eg, years considered, language, publication status) used as criteria for eligibility, giving rationale.                                                                                                        4
  Information sources                  7    Describe all information sources (eg, databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.                                                                                                                                  4
  Search                               8    Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                                                                                                                             4
  Study selection                      9    State the process for selecting studies (ie, screening, eligibility, included in systematic review, and if applicable included in the meta-analysis).                                                                                                                                                     4
  Data collection process              10   Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.                                                                                                                                  4
  Data items                           11   List and define all variables for which data were sought (eg, PICOS, funding sources) and any assumptions and simplifications made.                                                                                                                                                                       
  Risk of bias in individual studies   12   Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.                                                                                    
  Summary measures                     13   State the principal summary measures (eg, risk ratio, difference in means).                                                                                                                                                                                                                               5
  Synthesis of results                 14   Describe the methods of handling data and combining results of studies, if done, including measures of consistency (eg, *I*^2^) for each meta-analysis.                                                                                                                                                   5
  Risk of bias across studies          15   Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias, selective reporting within studies).                                                                                                                                                                5--6
  Additional analyses                  16   Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta- regression) if done, indicating which were prespecified.                                                                                                                                                             5--6
  **Results**                                                                                                                                                                                                                                                                                                                                         
  Study selection                      17   Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.                                                                                                                                           6
  Study characteristics                18   For each study, present characteristics for which data were extracted (eg, study size, PICOS, follow-up period) and provide the citations.                                                                                                                                                                6--7
  Risk of bias within studies          19   Present data on risk of bias of each study, and if available any outcome-level assessment (see item 12).                                                                                                                                                                                                  
  Results of individual studies        20   For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group; (b) effect estimates and confidence intervals, ideally with a forest plot.                                                                                                 7
  Synthesis of results                 21   Present results of each meta-analysis done, including confidence intervals and measures of consistency.                                                                                                                                                                                                   7
  Risk of bias across studies          22   Present results of any assessment of risk of bias across studies (see item 15).                                                                                                                                                                                                                           8
  Additional analysis                  23   Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta- regression \[see item 16\]).                                                                                                                                                                                    7
  **Discussion**                                                                                                                                                                                                                                                                                                                                      
  Summary of evidence                  24   Summarize the main findings, including the strength of evidence for each main outcome; consider their relevance to key groups (eg, health-care providers, users, and policymakers).                                                                                                                       9
  Limitations                          25   Discuss limitations at study and outcome level (eg, risk of bias), and at review level (eg, incomplete retrieval of identified research, reporting bias).                                                                                                                                                 10
  Conclusions                          26   Provide a general interpretation of the results in the context of other evidence, and implications for future research.                                                                                                                                                                                   11
  **Funding**                                                                                                                                                                                                                                                                                                                                         
  Funding                              27   Describe sources of funding for the systematic review and other support (eg, supply of data); role of funders for the systematic review.                                                                                                                                                                  

###### 

Quality-assessment scores

  Criteria                                            Score
  --------------------------------------------------- -------
                                                      
  Representativeness of case                          
  Selected from population cancer registry            2
  Selected from hospital                              1
  No method of selection described                    0
  Representativeness of control                       
  Population-based                                    3
  Mixed                                               2
  Hospital-based                                      1
  Not described                                       0
  Ascertainment of cancer case                        
  Histopathological confirmation                      2
  By patient medical record                           1
  Not described                                       0
  Control selection                                   
  Controls matched with cases by age and sex          2
  Controls matched with cases only by age or by sex   1
  Not matched or not described                        0
  Genotyping examination                              
  Genotyping done blindly and quality control         2
  Only genotyping done blindly or quality control     1
  Not described                                       0
  HWE                                                 
  HWE in the control group                            1
  HWD in the control group or not mentioned           0
  **Total sample size**                               
  \>1,000                                             3
  501--1,000                                          2
  201--500                                            1
  ≤200                                                0

**Abbreviations:** HWE, Hardy--Weinberg equilibrium; HWD, HW disequilibrium.

###### 

Definition of comparison models

  MMP     SNP          Homozygote     Heterozygote   Dominant            Recessive           Additive
  ------- ------------ -------------- -------------- ------------------- ------------------- ----------
                                                                                             
  MMP1    rs1799750    1G1G vs 2G2G   1G2G vs 2G2G   1G1G+1G2G vs 2G2G   1G1G vs 1G2G+2G2G   1G vs 2G
  MMP2    rs243865     CC vs TT       CT vs TT       CC+CT vs TT         CC vs CT+TT         C vs T
  MMP2    rs2285053    CC vs TT       CT vs TT       CC+CT vs TT         CC vs CT+TT         C vs T
  MMP2    rs1477017    AA vs GG       AG vs GG       AA+AG vs GG         AA vs AG+GG         A vs G
  MMP2    rs17301608   CC vs TT       CT vs TT       CC+CT vs TT         CC vs CT+TT         C vs T
  MMP2    rs11639960   AA vs GG       AG vs GG       AA+AG vs GG         AA vs AG+GG         A vs G
  MMP3    1171-5A/6A   5A5A vs 6A6A   5A6A vs 6A6A   5A5A+5A6A vs 6A6A   5A5A vs 5A6A+6A6A   5A vs 6A
  MMP3    1161-A/G     AA vs GG       AG vs GG       AA+AG vs GG         AA vs AG+GG         A vs G
  MMP3    5356-A/G     AA vs GG       AG vs GG       AA+AG vs GG         AA vs AG+GG         A vs G
  MMP7    rs11568818   AA vs GG       AG vs GG       AA+AG vs GG         AA vs AG+GG         A vs G
  MMP9    rs17576      AA vs GG       AG vs GG       AA+AG vs GG         AA vs AG+GG         A vs G
  MMP13   rs2252070    TT vs CC       TC vs CC       TT+TC vs CC         TT vs TC +CC        T vs C

###### 

Frequency of genotype in studies from meta-analysis. (A) MMP1 rs1799750; (B) MMP2 rs243865; (C) MMP7 rs11568818

  A                                                                                                                 
  -------------------------------------------- --------- ------------ ---------- ------------- -------- ----- ----- -----
  Albayrak S[@b36-cmar-10-5247]                MMP1      rs1799750    10         7             38       7     3     33
  Dos Reis ST[@b37-cmar-10-5247]               MMP1      rs1799750    21         52            27       11    34    55
  Tsuchiya N[@b38-cmar-10-5247]                MMP1      rs1799750    35         122           126      33    100   118
  Liao CH[@b39-cmar-10-5247]                   MMP1      rs1799750    51         88            79       96    193   147
  Białkowska K[@b40-cmar-10-5247]              MMP1      rs1799750    56         105           36       54    90    53
  **B**                                                                                                             
  **First author**                             **MMP**   **SNP**      **Case**   **Control**                        
  **CC**                                       **CT**    **TT**       **CC**     **CT**        **TT**               
  Dos Reis ST[@b37-cmar-10-5247]               MMP2      rs243865     50         38            12       59    20    21
  Srivastava P[@b41-cmar-10-5247]              MMP2      rs243865     101        78            11       131   62    7
  Yaykasli KO[@b42-cmar-10-5247]               MMP2      rs243865     51         7             3        42    4     0
  Adabi Z[@b43-cmar-10-5247]                   MMP2      rs243865     74         27            0        113   23    1
  Shajarehpoor Salavati L[@b44-cmar-10-5247]   MMP2      rs243865     34         11            5        41    7     6
  Białkowska K[@b40-cmar-10-5247]              MMP2      rs243865     104        79            14       101   78    18
  **C**                                                                                                             
  **First author**                             **MMP**   **SNP**      **Case**   **Control**                        
  **AA**                                       **AG**    **GG**       **AA**     **AG**        **GG**               
  Dos Reis ST[@b37-cmar-10-5247]               MMP7      rs11568818   33         41            26       25    39    36
  Białkowska K[@b40-cmar-10-5247]              MMP7      rs11568818   59         100           38       76    97    24

###### 

Frequency of genotype in studies from systematic review

  First author                      MMP     SNP          Case   Control                        
  --------------------------------- ------- ------------ ------ --------- ------ ------ ------ ------
  Srivastava P[@b41-cmar-10-5247]   MMP2    rs2285053    CC     CT        TT     CC     CT     TT
  101                               78      11           131    62        7                    
  Jacobs EJ[@b45-cmar-10-5247]      MMP2    rs1477017    AA     AG        GG     AA     AG     GG
  566                               645     206          639    624       178                  
  Jacobs EJ[@b45-cmar-10-5247]      MMP2    rs17301608   CC     CT        TT     CC     CT     TT
  541                               655     218          600    650       182                  
  Jacobs EJ[@b45-cmar-10-5247]      MMP2    rs11639960   AA     AG        GG     AA     AG     GG
  597                               645     168          675    610       154                  
  Srivastava P[@b46-cmar-10-5247]   MMP3    1171-5A/6A   5A5A   5A6A      6A6A   5A5A   5A6A   6A6A
  11                                38      101          4      64        132                  
  Srivastava P[@b46-cmar-10-5247]   MMP3    1161-A/G     AA     AG        GG     AA     AG     GG
  77                                66      7            103    80        17                   
  Srivastava P[@b46-cmar-10-5247]   MMP3    5356-A/G     AA     AG        GG     AA     AG     GG
  54                                84      12           84     89        27                   
  Dos Reis ST[@b37-cmar-10-5247]    MMP9    rs17576      AA     AG        GG     AA     AG     GG
  1                                 43      56           5      93        2                    
  Białkowska K[@b40-cmar-10-5247]   MMP13   rs2252070    TT     CT        CC     TT     CT     CC
  92                                87      18           104    78        15                   
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**Notes:** (**A**) Homozygote model; (**B**) heterozygote model; (**C**) dominant model; (**D**) recessive model; (**E**) additive model.](cmar-10-5247Fig2){#f2-cmar-10-5247}
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**Notes:** (**A**) Homozygote model; (**B**) heterozygote model; (**C**) dominant model; (**D**) recessive model; (**E**) additive model.](cmar-10-5247Fig4){#f4-cmar-10-5247}
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**Notes:** (**A**) Homozygote model; (**B**) heterozygote model; (**C**) dominant model; (**D**) recessive model; (**E**) additive model.](cmar-10-5247Fig5){#f5-cmar-10-5247}
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**Notes:** (**A**) Homozygote model; (**B**) heterozygote model; (**C**) dominant model; (**D**) recessive model; (**E**) additive model.](cmar-10-5247Fig6){#f6-cmar-10-5247}

###### 

Characteristics of included studies

  Study                                 Year   Country   Case-group sample type   Control-group source   Genotyping method   MMP     Polymorphism   Sample size (case/control)   HWE      Quality score
  ------------------------------------- ------ --------- ------------------------ ---------------------- ------------------- ------- -------------- ---------------------------- -------- ---------------
                                                                                                                                                                                          
  Albayrak et al[@b6-cmar-10-5247]      2007   Turkey    Blood                    HB                     PCR-RFLP            MMP1    rs1799750      55/43                        \<0.01   7
  Jacobs et al[@b7-cmar-10-5247]        2008   USA       Blood                    ND                     MassArray           MMP2    rs1477017      1,417/1,441                  0.182    9
  Jacobs et al[@b7-cmar-10-5247]        2008   USA       Blood                    ND                     MassArray           MMP2    rs17301608     1,414/1,432                  0.773    9
  Jacobs et al[@b7-cmar-10-5247]        2008   USA       Blood                    ND                     MassArray           MMP2    rs11639960     1,410/1,439                  0.357    9
  dos Reis et al[@b8-cmar-10-5247]      2009   Brazil    Tissue                   HB                     TaqMan              MMP1    rs1799750      100/100                      0.117    7
  dos Reis et al[@b8-cmar-10-5247]      2009   Brazil    Tissue                   HB                     TaqMan              MMP2    rs243865       100/100                      \<0.01   6
  dos Reis et al[@b8-cmar-10-5247]      2009   Brazil    Tissue                   HB                     TaqMan              MMP7    rs11568818     100/100                      0.035    6
  dos Reis et al[@b8-cmar-10-5247]      2009   Brazil    Tissue                   HB                     TaqMan              MMP9    rs17576        100/100                      \<0.01   6
  Tsuchiya et al[@b9-cmar-10-5247]      2009   Japan     Blood                    PB                     Direct sequencing   MMP1    rs1799750      283/251                      0.113    13
  Srivastava et al[@b10-cmar-10-5247]   2012   India     Blood                    Mixed                  PCR-RFLP            MMP2    rs243865       190/200                      0.919    10
  Srivastava et al[@b10-cmar-10-5247]   2012   India     Blood                    Mixed                  PCR-RFLP            MMP2    rs2285053      190/200                      0.581    10
  Srivastava et al[@b11-cmar-10-5247]   2013   India     Blood                    Mixed                  PCR-RFLP            MMP3    1171-5A/6A     150/200                      0.235    10
  Srivastava et al[@b11-cmar-10-5247]   2013   India     Blood                    Mixed                  PCR-RFLP            MMP3    1161A/G        150/200                      0.793    10
  Srivastava et al[@b11-cmar-10-5247]   2013   India     Blood                    Mixed                  PCR-RFLP            MMP3    5356A/G        150/200                      0.658    10
  Yaykasli et al[@b12-cmar-10-5247]     2014   Turkey    Blood                    HB                     PCR-RFLP            MMP2    rs243865       61/46                        0.758    6
  Adabi et al[@b13-cmar-10-5247]        2015   Iran      Blood                    PB                     PCR-RFLP            MMP2    rs243865       102/139                      0.885    10
  Salavati et al[@b14-cmar-10-5247]     2017   Iran      Tissue                   HB                     HRM                 MMP2    rs243865       50/54                        \<0.01   7
  Liao et al[@b32-cmar-10-5247]         2018   China     Blood                    HB                     PCR-RFLP            MMP1    rs1799750      218/436                      0.03     7
  Białkowska et al[@b33-cmar-10-5247]   2018   Poland    Blood                    PB                     TaqMan              MMP1    rs1799750      197/197                      0.226    8
  Białkowska et al[@b33-cmar-10-5247]   2018   Poland    Blood                    PB                     TaqMan              MMP2    rs243865       197/197                      0.60     8
  Białkowska et al[@b33-cmar-10-5247]   2018   Poland    Blood                    PB                     TaqMan              MMP7    rs11568818     197/197                      0.411    8
  Białkowska et al[@b33-cmar-10-5247]   2018   Poland    Blood                    PB                     TaqMan              MMP13   rs2252070      197/197                      0.943    8

**Abbreviations:** HB, hospital-based; PB, population-based; ND, not described; HWE, Hardy--Weinberg equilibrium; PCR-RFLP, polymerase chain-reaction restricted-fragment-length polymorphism; HRM, high-resolution melting.

###### 

Meta-analysis of association between MMP1 rs1799750 and prostate cancer

  Comparison model   Subgroup   Studies   OR (95% CI)         *P*~OR~[a](#tfn2-cmar-10-5247){ref-type="table-fn"}   *I*^2^ (%)   *P*~het~ [b](#tfn3-cmar-10-5247){ref-type="table-fn"}
  ------------------ ---------- --------- ------------------- ----------------------------------------------------- ------------ -------------------------------------------------------
                                                                                                                                 
  Homozygote         Overall    5         1.16 (0.91--1.47)   0.237                                                 15.9         0.313
                     Blood      4         1.06 (0.82--1.37)   0.632                                                 0            0.919
  Heterozygote       Overall    5         1.12 (0.94--1.33)   0.223                                                 12.9         0.332
                     Blood      4         1.06 (0.87--1.27)   0.575                                                 0            0.648
  Dominant           Overall    5         1.09 (0.94--1.27)   0.251                                                 0.4          0.404
                     Blood      4         1.04 (0.89--1.22)   0.617                                                 0            0.832
  Recessive          Overall    5         1.09 (0.87--1.37)   0.471                                                 0            0.666
                     Blood      4         1.03 (0.81--1.31)   0.818                                                 0            0.982
  Additive           Overall    5         1.09 (0.97--1.23)   0.163                                                 34.5         0.191
                     Blood      4         1.04 (0.91--1.18)   0.57                                                  0            0.871

**Notes:**

*P*-value of *Z*-test for OR;

*P*-value of *Q*-test for heterogneity.

###### 

Meta-analysis of association between MMP2 rs243865 and prostate cancer

  Comparison model   Subgroup   Studies   OR (95% CI)         *P*~OR~[a](#tfn4-cmar-10-5247){ref-type="table-fn"}   *I*^2^ (%)   *P*~het~[b](#tfn5-cmar-10-5247){ref-type="table-fn"}
  ------------------ ---------- --------- ------------------- ----------------------------------------------------- ------------ ------------------------------------------------------
                                                                                                                                 
  Homozygote         Overall    6         1.0 (0.84--1.20)    0.97                                                  0            0.998
                     Blood      4         0.99 (0.81--1.21)   0.92                                                  0            0.986
                     Tissue     2         1.06 (0.71--1.56)   0.787                                                 0            0.825
  Heterozygote       Overall    6         1.08 (0.84--1.40)   0.54                                                  0            0.894
                     Blood      4         1.01 (0.76--1.34)   0.967                                                 0            0.972
                     Tissue     2         1.48 (0.82--2.68)   0.919                                                 0            0.777
  Dominant           Overall    6         1.01 (0.87--1.18)   0.875                                                 0            0.997
                     Blood      4         1.0 (0.84--1.18)    0.963                                                 0            0.994
                     Tissue     2         1.08 (0.77--1.50)   0.66                                                  0            0.778
  Recessive          Overall    6         0.9 (0.76--1.06)    0.206                                                 0            0.957
                     Blood      4         0.91 (0.75--1.09)   0.305                                                 0            0.801
                     Tissue     2         0.87 (0.60--1.25)   0.442                                                 0            0.886
  Additive           Overall    6         0.96 (0.86--1.08)   0.521                                                 0            0.987
                     Blood      4         0.96 (0.85--1.09)   0.511                                                 0            0.892
                     Tissue     2         0.98 (0.77--1.26)   0.903                                                 0            0.871

**Notes:**

*P*-value of *Z*-test for OR;

*P*-value of *Q*-test for heterogeneity.

###### 

Meta-analysis of association between MMP7 rs11568818 and prostate cancer

  Comparison model   Studies   OR (95% CI)         *P*~OR~[a](#tfn6-cmar-10-5247){ref-type="table-fn"}   *I*^2^ (%)   *P*~het~[b](#tfn7-cmar-10-5247){ref-type="table-fn"}
  ------------------ --------- ------------------- ----------------------------------------------------- ------------ ------------------------------------------------------
                                                                                                                      
  Homozygote         2         0.95 (0.67--1.37)   0.796                                                 45.9         0.174
  Heterozygote       2         0.98 (0.72--1.33)   0.908                                                 0            0.435
  Dominant           2         0.99 (0.77--1.26)   0.917                                                 0            0.39
  Recessive          2         0.91 (0.66--1.27)   0.592                                                 53.7         0.142
  Additive           2         0.97 (0.80--1.17)   0.72                                                  56           0.132

**Notes:**

*P*-value of *Z*-test for OR;

*P*-value of *Q*-test for heterogeneity.

###### 

Systematic review of association between MMPs polymorphisms and prostate cancer

  A Homozygote model, Heterozygote model, Dominant model                                                                                                      
  -------------------------------------------------------- ------------ ----------------------- ------- ---------------------- ------- ---------------------- -------
                                                                                                                                                              
  MMP2                                                     rs2285053    0.95 (0.663--1.361)     0.780   0.975 (0.617--1.542)   0.915   0.976 (0.735--1.297)   0.868
  MMP2                                                     rs1477017    0.937 (0.807--1.089)    0.398   0.974 (0.842--1.128)   0.726   0.975 (0.876--1.086)   0.646
  MMP2                                                     rs17301608   0.929 (0.797--1.083)    0.346   0.960 (0.831--1.109)   0.583   0.969 (0.870--1.080)   0.568
  MMP2                                                     rs11639960   0.958 (0.827--1.111)    0.573   0.994 (0.857--1.153)   0.933   0.986 (0.886--1.098)   0.802
  MMP3                                                     1171-5A/6A   3.339 (1.035--10.774)   0.044   0.837 (0.530--1.322)   0.446   0.961 (0.629--1.468)   0.853
  MMP3                                                     1161A/G      1.068 (0.712--1.603)    0.751   1.096 (0.702--1.711)   0.686   1.042 (0.768--1.413)   0.792
  MMP3                                                     5356A/G      1.081 (0.684--1.709)    0.738   1.14 (0.763--1.706)    0.522   1.064 (0.782--1.447)   0.695
  MMP9                                                     rs17576      0.025 (0.002--0.242)    0.001   0.444 (0.281--0.702)   0.001   0.449 (0.286--0.705)   0.001
  MMP13                                                    rs2252070    0.957 (0.653--1.402)    0.822   0.988 (0.653--1.494)   0.954   0.984 (0.739--1.309)   0.909

  B Recessive model, Additive model                                                                       
  ----------------------------------- ------------ ----------------------- ------- ---------------------- -------
                                                                                                          
  MMP2                                rs2285053    0.812 (0.585--1.125)    0.21    0.91 (0.735--1.125)    0.383
  MMP2                                rs1477017    0.901 (0.787--1.031)    0.129   0.95 (0.875--1.032)    0.226
  MMP2                                rs17301608   0.913(0. 796--1.048)    0.195   0.951 (0.875--1.034)   0.238
  MMP2                                rs11639960   0.903 (0.791--1.030)    0.129   0.958 (0.882--1.040)   0.301
  MMP3                                1171-5A/6A   3.667 (1.145--11.741)   0.029   1.111 (0.765--1.615)   0.581
  MMP3                                1161A/G      0.997 (0.693--1.433)    0.986   1.026 (0.814--1.292)   0.83
  MMP3                                5356A/G      0.857 (0.573--1.281)    0.452   0.996 (0.784--1.266)   0.975
  MMP9                                rs17576      0.2 (0.023--1.743)      0.145   0.437 (0.292--0.653)   0.001
  MMP13                               rs2252070    0.885 (0.628--1.247)    0.484   0.948 (0.763--1.177)   0.627
